Cargando…

Characterization of anti-drug antibodies and drug-responsive B-lymphocytes in piperacillin hypersensitive patients with cystic fibrosis

Detalles Bibliográficos
Autores principales:	Amali, Mohammed, Sullivan, Andrew, Farrell, John, Meng, Xaoli, Jenkins, Roz, Whitaker, Paul, Peckham, Daniel, Park, B Kevin, Naisbitt, Dean J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127985/ http://dx.doi.org/10.1186/2045-7022-4-S3-P113

Ejemplares similares

Detection of interleukin-22 secreting T-cells in piperacillin hypersensitive patients with cystic fibrosis
por: Sullivan, Andrew, et al.
Publicado: (2014)

Characterization of the TCR V repertoire of piperacillin-specific T-cells
por: Al-Attar, Zaid, et al.
Publicado: (2014)

In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs
por: Hammond, Sean, et al.
Publicado: (2021)

Why drug exposure is frequently associated with T-cell mediated cutaneous hypersensitivity reactions
por: Line, James, et al.
Publicado: (2023)

Piperacillin-Induced Immune Hemolytic Anemia in an Adult with Cystic Fibrosis
por: Bandara, Mahesh, et al.
Publicado: (2010)

Antigen exposure required for T cell activation
por: Meng, Xiaoli, et al.
Publicado: (2014)

Isoniazid-specific T-cell Responses in patients with anti-tuberculosis drug related liver injury
por: Usui, Toru, et al.
Publicado: (2014)

Severe piperacillin–tazobactam‐induced hemolysis in a cystic fibrosis patient
por: Kerkhoff, Andrew D., et al.
Publicado: (2017)

Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients
por: Ariza, Adriana, et al.
Publicado: (2022)

Negative regulation by Programmed Death Ligand-1 during drug-specific priming of T-cells and the influence of Programmed Death-1 on effector T-cell function
por: Gibson, Andrew, et al.
Publicado: (2014)

HLA-DQ restricted activation of nitroso-sulfamethoxazole-specific CD4+ T-lymphocytes
por: Ogese, Monday, et al.
Publicado: (2014)

Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: A case report
por: Song, Gao, et al.
Publicado: (2022)

Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
por: Sawant, Akhil, et al.
Publicado: (2018)

Hypersensitivity to parenteral antibiotics in patients with cystic fibrosis
por: Roehmel, Jobst, et al.
Publicado: (2014)

Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices
por: Orenstein, David M., et al.
Publicado: (2015)

Dapsone hypersensitivity syndrome
por: Zhao, Qing, et al.
Publicado: (2023)

Drug treatment of cystic fibrosis
por: Bruorton, Matthew, et al.
Publicado: (2022)

Autism and Piperacillin-tazobactam-induced Hypersensitivity Vasculitis: A Silent Malady
por: Kolli, Sindhura, et al.
Publicado: (2019)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Characterization of Drug-Specific CD4(+) T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions
por: Jaruthamsophon, Kanoot, et al.
Publicado: (2023)

Piperacillin/Tazobactam-Associated Hypersensitivity Syndrome with Overlapping Features of Acute Generalized Exanthematous Pustulosis and Drug-Related Rash with Eosinophilia and Systemic Symptoms Syndrome
por: Kim, Tae In, et al.
Publicado: (2016)

Abs No: HLA-A*31:01 positive hypersensitive patient
por: Lichtenfels, Maike, et al.
Publicado: (2014)

Drug Fever Due to Piperacillin/Tazobactam Loaded into Bone Cement
por: Park, Hyun Bum, et al.
Publicado: (2011)

Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
por: Hammond, Sean, et al.
Publicado: (2021)

Advances in the Cystic Fibrosis Drug Development Pipeline
por: Esposito, Christine, et al.
Publicado: (2023)

Myocardial infarction in an adult with cystic fibrosis and heart and lung transplant
por: Eaden, James, et al.
Publicado: (2013)

Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury
por: Kim, Seung-Hyun, et al.
Publicado: (2016)

Diclofenac Hypersensitivity: Antibody Responses to the Parent Drug and Relevant Metabolites
por: Harrer, Andrea, et al.
Publicado: (2010)

Drug hypersensitivity in drug-resistant tuberculosis
por: Katran, Zeynep Yegin, et al.
Publicado: (2023)

Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
por: Harwood, Kiera H., et al.
Publicado: (2021)

Analysis of IV Drugs in the Hospital Workflow by Raman Spectroscopy: The Case of Piperacillin and Tazobactam
por: Chrisikou, Ioanna, et al.
Publicado: (2021)

Isavuconazole/piperacillin/tazobactam/voriconazole: Drug-induced liver injury: case report
Publicado: (2022)

Drug reaction with eosinophilia and systemic symptoms syndrome related to piperacillin-tazobactam use
por: Bai, M, et al.
Publicado: (2022)

Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs
por: Li, Hongyu, et al.
Publicado: (2019)

Comparison of basophil activation test and lymphocyte transformation test as diagnostic assays for drug hypersensitivity
por: Adachi, Takeya, et al.
Publicado: (2014)

Antibiotic hypersensitivity in cystic fibrosis – Low frequency of anaphylaxis over 16 000 courses
por: Kowalik, Aleksandra, et al.
Publicado: (2022)

European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre
por: Conway, Steven, et al.
Publicado: (2014)

Predicting CFTR activity with front-runner cystic fibrosis drugs
por: Becq, Frédéric
Publicado: (2015)

Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients
por: Satana, Dilek, et al.
Publicado: (2014)

Drug hypersensitivity in children in Brazil
por: Ensina, Luis Felipe, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gd8m8s69g5c2rl5bvl2ld7qad7